[Featured Stock] Vuno's Chest X-ray AI Solution Receives US FDA Approval... 'Bullish'

Vuno is showing strong performance. The news that its chest X-ray technology has been approved in the United States appears to have had an impact.

As of 1:36 PM on the 19th, Vuno was trading at 28,400 KRW, up 2,000 KRW (7.58%) compared to the previous trading day.

On the same day, Vuno announced that it had obtained approval (510k Clearance) from the U.S. Food and Drug Administration (FDA) for its AI-based chest X-ray reading and opinion screening medical device, 'VUNO Med®-Chest X-ray™ Triage.'

VUNO Med Chest X-ray Triage analyzes chest X-ray images. It is an AI solution that quickly screens for pneumothorax and pleural effusion. It is expected to contribute to rapid treatment in medical settings such as emergency rooms by quickly providing medical staff with automatic classification results regarding the presence or absence of pneumothorax and pleural effusion.